| Name | Title | Contact Details |
|---|
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche
Leap is developing novel drugs to change the practice of cancer medicine
maryville academy is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.